One contribution of 15 to a theme issue 'Bioengineering in women's health, volume 2: pregnancy-from implantation to parturition'. In the past few decades, the placenta became a very controversial topic that has had many researchers and pharmacists discussing the significance of the effects of pharmaceutical drug intake and how it is a possible leading cause towards birth defects. The creation of an in vitro microengineered model of the placenta can be used to replicate the interactions between the mother and fetus, specifically pharmaceutical drug intake reactions. As the field of nanotechnology significantly continues growing, nanotechnology will become more apparent in the study of medicine and other scientific disciplines, specifically microengineering applications. This review is based on past and current research that compares the feasibility and testing of the placenta-on-a-chip microengineered model to the previous and underdeveloped in vivo and ex vivo approaches. The testing of the practicality and effectiveness of the in vitro, in vivo and ex vivo models requires the experimentation of prominent pharmaceutical drugs that most mothers consume during pregnancy. In this case, these drugs need to be studied and tested more often. However, there are challenges associated with the in vitro, in vivo and ex vivo processes when developing a practical placental model, which are discussed in further detail.
Introduction
The human placenta is an extremely critical and complicated organ that performs a variety of functions. Those functions are comprised of a few of the following: ensuring the safety and security of fluid, nutrient, and oxygen circulation and flow; the removal of waste products and carbon dioxide; and the shielding from harmful diseases, infections, and xenobiotics from the mother to fetus. The performance of these actions supports the development and maturity of the fetus [1] [2] [3] [4] . The structure of the placenta is composed of a placental trophoblast and fetal capillary endothelium layer. The two cell layers separate the fetal circulation from the maternal blood, ensuring that no intermingling occurs between the two blood flows [5] . Unfortunately, studying and monitoring the placenta is very difficult, considering the structure of the placenta goes through a considerable amount of alterations during pregnancy [6] . Not to mention, as pregnancies progress within mothers, more dramatic alterations begin taking place in their placental barrier, making the testing and monitoring even more challenging [6] . Although the placenta is very difficult to examine and study, the knowledge that humans are gaining from the placenta proves to be a vital source for humanity's understanding of the human placenta's overall behaviour and system. Therefore, the functionalities and structure of the placenta play a vital role in the testing, surveillance, and understanding of the placental barrier's properties and purpose in the human body. Understanding the physiology behind the placenta creates a foundation for researchers to pave a model, for the scientific community and pharmaceutical industry, towards the testing and better understanding of the human placenta.
Until the past couple of decades, there was an idea circulating around researchers, pharmacists and the public that the placenta is an impenetrable barrier that does not impose any fatal or severe effects upon the mother or fetus [7] . However, the discovery of thalidomide-induced birth defects in the late 1960s dismantled that argument [7] . A few years after the discovery of the thalidomide-induced birth defects, Boston University's Slone Epidemiology Center Birth Defects Study (BDS) began conducting an array of detailed interviews with a diverse selection of pregnant women, which still takes place annually [8] . The intent of this programme is to survey the medication that pregnant women are taking throughout the duration of their pregnancy. When the data are collected, researchers analyse the trend of medication intake by pregnant women and compare the intake towards the rise, causes and formation of birth defects. The collection of these data supports the proposed argument by researchers around the globe that pregnant women are taking medications more frequently and these medications need to be studied more thoroughly. The pharmaceutical industry is also faced with a considerable amount of complaints and concerns, surrounding their integrity and the safety of their drugs and adequacy [9] . To bring statistics into the argument, statistics display the fact that approximately 45.3% of pregnant women use prescription medicine, excluding vitamins [10] . As the growth and scepticism of pharmaceutical and over-the-counter drugs become more popular for pregnant women, the testing of the feasibility and effectiveness of these drugs needs to be taken more seriously in order to prevent these increasing measures in birth defects. For example, the development and utilization of in vivo systems, and ex vivo and in vitro devices has helped scientists to study the effects and harms that these drugs are imposing on the human placenta.
A variety of in vivo systems, and ex vivo and in vitro devices have been developed, for the most part, to mimic and replicate the metabolism process and active transport in the human placenta [7, 11] . The development of the placenta-on-a-chip and other in vivo and ex vivo systems avoids the risk of the rupturing and disturbance of the fetus and mother [12] [13] [14] . The use of these instruments creates a more viable and systematic approach towards the testing and understanding the effects that pharmaceutical and other medicated drugs inflict upon the placenta. However, scientists have become increasingly more interested in the placenta-on-a-chip model for testing, especially in the past few years. While the in vivo and ex vivo systems do recapitulate a few of the behaviours and functions performed by the human placenta, they struggle with the resources and technology to carry out these tests effectively. Nonetheless, these approaches are being overshadowed by the growing desire and promise that the in vitro models possess. With growing interest and development in the field of nanotechnology, the placenta is being infused into nanomedical related applications, particularly on-a-chip utilization [7, 15] . The microengineered placenta-on-a-chip is the face of a new generation of technology that is becoming ever more demanding in the study of the placenta. Although there are numerous amounts of challenges involved in the in vitro models, the models' abilities can be used to replicate the effects that pharmaceutical drugs are inflicting on the placental barrier. Most importantly, though, applying the placenta-ona-chip to the study and understanding of the placenta will give rise to the clarification on how pharmaceutical drugs and diseases are leading causes of birth defects and mutations in the mother's placental barrier.
Human placenta
The placenta (figure 1) serves as a vital organ in the production and growth of the fetus. The placenta performs as the kidneys, lungs, gut and liver throughout the duration of pregnancy in order to keep the fetus alive [16, 17] . Based on the physiology of the placenta, the placental barrier is structurally defined by the placental trophoblast and fetal capillary endothelium layer, because they are the foundation and building blocks towards the development of other components of the placental barrier [5] . The combination of the placental trophoblast and endothelium layer supports the development of the chorionic villi. Throughout most of pregnancy, the placenta's chorionic villi serve as the main structural component of the placental barrier, which is composed primarily of cytotrophoblasts. Cytotrophoblasts are the inner layer of the trophoblast and the stem cells for the syncytiotrophoblast. The main roles the syncytiotrophoblast plays in the development of the placenta are the synthesization of progesterone and oestrogens, and the operation of the endocrine unit. Along with the royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 synthesization and operation of oestrogens, progesterone, and endocrine, the syncytiotrophoblast plays a significant role in the production of the placental growth hormone and peptide hormone [18] . To take into consideration, the separation between the cytotrophoblast and the syncytiotrophoblast is largely dependent on the syncytiotrophoblast; the syncytiotrophoblast covers each villus after being compressed into a layer that separates the lucanue from the cytotrophoblast layer. Furthermore, the separation of the two layers creates intervillous spaces that ensure the growth of the fetus [19] . In the course of the developments and processes carried out by the cytotrophoblasts and syncytiotrophoblast, their actions occur throughout the beginning portion of pregnancy, when the fetal organ development occurs in an environment with low oxygen pressure [16] . Scientists need to acquire a great deal of knowledge regarding the physiology behind the placental barrier in order to mimic the functionalities of the human placenta for pharmaceutical and other experimental purposes.
Understanding the solute across the placenta is critical when examining the placental barrier mechanisms. The migration of solute across the placental barrier, for the most part, begins in the later developments of the fetus when the structural components of the placental barrier are able to withstand the diffusion of fluids. In order for fetal growth to perform efficiently, the exchange of products and nutrients across the placenta is essential. Scientists still struggle to fully understand the inner mechanisms towards the exchange of fetal metabolism over the placental barrier. However, scientists have been able to discover and formulate a significant amount of information that gives researchers a general idea of the inner mechanisms of the placental barrier. In large part, the concentration gradient of the substance, extent, and thickness of the placental barrier are needed for the performance of the transfer of nutrients [18, 19] . The paracellular permeability and electrical potential difference are both major factors that come into play when studying the solute exchange across the placenta. Another significant mechanism towards the transferring of nutrients across the placenta is the functions that the transporter protein carries out: transporting glucose, hydrophobic molecules and amino acids across the placenta. In fact, transporter proteins are located in the plasma membrane along with carriers, which are membrane proteins as well. The purpose of the carriers is to merge themselves with the solute and transport the solute to other parts of the membrane, similarly to the transporter proteins [20, 21] . The functionalities and system of exchange of fluids across the placental barrier is an important part of the placenta. In order for researchers to replicate the human placenta for experimental purposes, they must take the diffusion across the placental barrier and the complex physiology of the placenta into consideration when developing the most practical model possible.
In vivo
The in vivo model for testing is an underdeveloped approach towards the study and testing of pharmaceuticals for the better understanding of the human placenta [22] . One of the most common and extended methods of testing is the experimentation on animal subjects, especially for medicalrelated purposes. The use of pregnant animals is a favoured in vivo model for testing and studying the functionalities and pharmaceutical effects of medicated drugs across the placenta [23] . Rodents and mammals, like rats [24] [25] [26] , rabbits [27, 28] , camels [29 -31] and pigs [32] [33] [34] , have all served as previous subjects for an in vivo model towards the replication of the functionalities and structure of the human placenta. Nonetheless, animal models vary dramatically from human physiology, making data comparisons difficult to match from an animal to a human placenta [35] . Although scientists have used a variety of animal placentas for pharmaceutical testing, the mouse and sheep placentas are the two in vivo subjects that will be discussed in further detail. The sheep and mouse placenta models are chosen for discussion for two particular reasons. One, the mouse and sheep models have proven to be popular approaches towards the evaluation and transability of using their placentas in place of human placentas for pharmaceutical testing, which is evident from the upcoming table and explained in the upcoming sections. Secondly and most importantly, though, the mouse model has the closest placental structure with the human placenta [36] , and the fetal-placental vascular structure in the sheep model shares more resemblances with the human placenta than the majority of other mammals [14] . Similar physiological characteristics between the mouse, sheep and human placenta make for more effective assessments and support for the in vivo's background in pharmaceutical and functional analysis evaluations.
Mouse and sheep models
Researchers of the past and present are still fixated on the idea of testing on animals, believing that genetically mutated animals, particularly the mouse (figure 2b1-b3), can be used to replicate the human placenta (figure 2a1-a3). The mouse is one of the most important, if not the best, subjects for in vivo testing of the placenta. The reason is that the mouse placental barrier is the closest structure to the human placenta due to the correspondence of both of their designs being a haemochorial type [36] . The use of mouse trophoblast is also an alternative solution for the difficulty in obtaining primary human tissue, because researchers can efficiently use trophoblast stem cells to mimic the features of the human syncytiotrophoblasts [38] . In addition to the resembling physiological traits between the two placentas, the mouse and human placenta both have a similar diffusion coefficient of water and allowance of inert hydrophilic solutes. Similar placental physiological exchange between the human and mouse placenta has played a vital role in the development and progression of the mouse model [36] . Not to mention, for most scientists, time is a valuable factor when carrying out experiments and analysis, which makes mice a leading candidate for experimentation. The reason is that mice are particularly easy to breed and handle, due to their high reproductive rate and rapid development [39] . Overall, though, scientists have acquired a considerable amount of information regarding the comparable biological and genetic characteristics between the mouse and human placenta in the past few decades, supporting the argument that the mouse model is an appropriate model for study [36] .
While the mouse placenta does provide a comparative advantage over other rodents and mammals when testing the effects of medicated drugs on the placenta, scientists have spent a considerable amount of time evaluating the feasibility of the sheep placenta (figure 2c1-c3) for future pharmaceutical testing. The reason is that researchers have royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 achieved an extensive amount of progress modifying and assessing the sheep placenta for medical and analytical related purposes. For instance, the nutrient metabolism and respiration of the mammalian fetus are a couple of examples of the knowledge humans have gained from studying pregnant sheep [40] . Scientists have also taken advantage of the sheep placenta when testing and exploring the maternalfetal structure and interactions when developing an in vivo model to examine placental nutrient transfer [40] . To mention however, sheep, for the most part, have researchers surgically perform on their placenta when the fetus has reached a substantial weight and the maturity is quite high. In contrast though, the mouse model usually has the scientists genetically modify the mouse placenta and operate the surgical procedures earlier in the fetal development [41] . Nevertheless, the previous testing for nutrient metabolism and placental nutrient transfer on the sheep placenta was only made possible due to the shared physiological traits between the sheep and human placenta. Since the sheep and human placenta share alike biological qualities, scientists have been able to conduct and translate medicated-drug-related testing from the sheep to the human placenta. Corresponding physiological characteristics can be found in the villous tree of the sheep cotyledon, which shares a similar structure to the villous tree of the human placenta. Additionally, both the sheep and human placentas are structurally divided up into cotyledons and share alike fetal placental vascular structures [42] . Nonetheless, scientists have acquired a significant volume of knowledge regarding the feasibility and structure of the sheep model for in vivo pharmaceutical testing, making the following approach a candidate for study. To summarize, as researchers continue taking advantage of the mouse and sheep approaches, scientists will grasp a fuller understanding of how they can manipulate and apply these models towards the better understanding of how medicated drugs affect the human placenta.
Studies concerning the mouse and sheep models
Since the mouse and sheep models are studied quite frequently among scientists, researchers have been able to conduct a variety of experiments across the mouse and sheep placentas. royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 mouse toxicity/drug testing test the effects of lithium, homocysteine and alcohol in mouse placenta the mouse placenta can prevent intrauterine growth retardation (IUGR) caused by lithium, homocysteine and alcohol [43] evaluated the effects of progesterone on breast cancer resistance protein (BCRP) in mouse placenta in vivo increased levels of progesterone did not have any noticeable effects on BCRP [44] tested for thalidomide-induced limb irregularities in humanized cytochrome P450 3A (CYP3A) mouse model in vivo limb abnormalities were recorded, human CYP3A was shown in mouse placenta, concluding that mouse model can predict toxicity in humans [45] analyse effects that anti-oxidant tempol has on mouse model during fetal growth in vivo tempol improved the fetal growth in mouse placenta, and increased the velocity of uterine artery blood flow [46] functional analysis use gestation in trophoblast of a mouse placenta to study subcellular localization and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expressions GAPDH may have multiple purposes in trophoblast cells [47] evaluated venous morphological, functional, and arterial differences in the mouse fetoplacental vascular network fetoplacental veins and arteries differ between their branching scaling rules, and fetoplacental resistance is made up 26% of veins [48] evaluate interleukin-(IL)11 in mouse placenta, and IL1b and TNFa effects on placental villous explants IL11 turned out to be regulated by pro-inflammatory cytokines IL1b, but not TNFa [49] examined human placental mesenchymal stromal cells (PMSC) in a mouse model in vivo PMSC had positive effects on neovascularization in mouse model in vivo [50] characterized lymphocyte antigen 6, locus E (LY6E) in mouse placenta syncytiotrophoblast differentiation is expressed from LY6E and may be found in progenitors [51] studied parasite dynamics in mouse placental labyrinth layer using intravital microscopy infected red blood cells can be internalized by trophoblast cells, and quick removal of particles inside blood flow is a characteristic of placental blood flow [52] evaluate Cited2's effects on vascularization and trophoblast formation on mouse placenta in vivo normal placental vascularization and development requires Cited2 to promote embryo growth [53] examined how transcriptional co-repressor TLE3 promotes development if giant trophoblast cells in mouse placenta growth and differentiation of trophoblast giant cells is regulated by TLE3, and TLE3 has placenta deficiencies [54] tested Argonaute 2 (AGO2) effects on differentiation of mouse embryonic stem cells in vivo extra-embryonic endoderm genes need AGO2, and AGO2 plays a significant role in stem cell differentiation [55] evaluated BCRP in mouse placenta in vivo mouse placenta expressed the fact that BCRP limits the effects of medicated drugs during pregnancy [44] studied the transfer of maternal cholesterol in mouse in vivo the transfer of maternal cholesterol was evident in the mouse, and the yolk and placenta are the sites for intermediate passage [56] (Continued.)
royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 sheep toxicity/drug testing evaluated triclosan in sheep placenta triclosan is a potent inhibitor of sulfotransferase in the sheep placenta, and reduces the total placental oestrogen secretion [57] examine the uptake of transdermal fentanyl in pregnant sheep the fentanyl transfer rate was 77%, and recorded low pain scores after laparotomy and hysterotomy [58] analyse the rosiglitazone in the sheep plasma and the effects rosiglitazone has on pregnant sheep in vivo study proves to be ideal for pharmacokinetic studies in sheep model, and successfully applied the determination of rosiglitazone in pregnant sheep [22] functional analysis tested for the enhancement of the cytokine expression from maternal obesity (MO) in sheep placenta MO increased the placental inflammatory responses of kappa-light-chain-enhancer of activated B cells (NF-kB) and c-Jun N-terminal kinase (JNK)/c-Jun, thence enhancing cytokines [59] test the effects that human amnion epithelial cells (hAEC) have on sheep acute inflammatory response in vivo hAEC does not significantly alter the acute fetal inflammatory response in pregnant sheep [60] examined the impact that chronic maternal stress (CMS) has on fetal stress sensitivity and maternal-fetal stress transfer in sheep placenta CMS promotes maternal-fetal stress transfer, and increases fetal hypothalamus -pituitary-adrenal (HPA) responsiveness [61] evaluate the effects that hypoxemia has on fetal ventricular deformation in sheep in vivo fetal cardiac function in altered ventricular demoration is changed substantially due to hypoxemia [62] measure the effects of genotype and nutrient on prion protein (PrPC) gene in sheep placenta genotype affects PrPC but not the protein expression levels [63] analyse carbohydrate metabolism in sheep placenta in vivo glucose may form fructose though sorbitol in placental cells [64] use sheep placenta to evaluate electron microscopy of the localization of ferric iron in vivo ferric iron was observed in the epithelial cytoplasmic matrix, and liberated from digested haemoglobin [65] evaluated caspase mechanisms of apoptosis across sheep model in vivo when apoptosis-inducing factor (AIF) and telomerase activity (TA) are increased, apoptotic mechanisms do not require caspase signalling [66] royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 of testing, details regarding experimentation, and conclusions from the analysis. Table 1 portrays an array of studies towards the evaluation of medicated drugs, toxins and the functional analysis of the mouse placental barrier in vivo. As illustrated, researchers have been able to test a few medicated drugs like tempol [46] , progesterone [44] , thalidomide [45] across the mouse placenta, and mimic a substantial quantity of the human placental features. More importantly, the collection of these data results on the mouse model proves to be vital when comparing the results towards previous data of the effects of these medicated drugs on the human placenta [39] . Fortunately, results in correlation with the effects that tempol, progesterone and thalidomide have on fetal growth and glucose metabolism showed evident similarities towards the natural reactive effects they impose on the human placental barrier. To acknowledge, however, tempol, progesterone and thalidomide are popular medications that most pregnant women consider throughout their pregnancy and require to be studied more often for behavioural interactions with the fetus. Nonetheless, if it was not for the mouse alternative tissue in place for human tissue, the imitation of tempol, progesterone and thalidomide across the placenta would not be as efficiently carried out as with other rodents and mammals [38] . In addition to medicated drug testing on the mouse placenta, there is an immense amount of evaluating pertaining to the functional analysis and inner structure of the mouse placenta, retaining towards the transability of using the mouse placenta in place of the human placenta for pharmaceutical testing. For example, scientists tested mesenchymal stromal cells [50] , maternal cholesterol [56] , proteins [44] and other characteristics across the mouse placenta in order to decide if the mouse placenta shares comparable biological characteristics with the human placenta. Based on data and conclusions of table 1, researchers found that the mouse placenta shares similar protein and cellular features with the human placental barrier. Thus, the mouse placenta may be an appropriate model for medicated drug testing in the near future, because of the shared qualities in physiological features and medicated drug reactions with the human placenta.
While the mouse placenta has had a substantial amount of testing performed across the model's placenta, the sheep approach has proven to have a solid record of accomplishment of assessing as well. Ever since researchers have been taking advantage of the sheep placenta, they have been able to evaluate the inner mechanisms of the sheep placental barrier, and the effects that triclosan [57] , rosiglitazone [22] , and transdermal fentanyl [58] have on fetal growth and glucose metabolism. Based on table 1, there has been a substantial amount of accomplishments pertaining towards the evaluation of the functional analysis and inner mechanisms of the sheep placental barrier in vivo. Similarly, with the mouse model, from fluid transfer to membrane and protein examinations, the sheep model has been a reliable method for the study and transability of the model's functional analysis for the better understanding of the human placenta. Nonetheless, there have also been a few medicated tests performed across the sheep placental barrier. Those tests pertain to the evaluation of the effects that triclosan, transdermal fentanyl, and rosiglitazone have on the sheep placenta. To make notice, triclosan, transdermal fentanyl, and rosiglitazone are common medications that women take during pregnancy and there is a modest volume of information on their implications for fetal growth. Nevertheless, the medicated drug testing conclusions from table 1 revealed whether the sheep placenta is an alternative and suitable approach for medicated drug testing in place of the human placenta. Fortunately, results in correlation with the effects that triclosan, transdermal fentanyl, rosiglitazone have on fetal growth and glucose metabolism demonstrated evident resemblances towards the normal reactive effects they impose on the human placental barrier based from the conclusions of their research in table 1. Therefore, the sheep placenta may also be an appropriate model for pharmaceutical experimentation in the upcoming future, considering the human placenta's similar qualities in medicated drug reactions and physiological features. Moreover, the fact that scientists have executed a countless amount of functional analysis tests and a few pharmaceutical evaluations on the sheep and mouse models supports the argument that both models have the potential to be alternative approaches for studying the human placenta in vivo.
Mouse model limitations
Despite the advantages as serving as an in vivo model for testing, the mouse placenta has only partially been able to prove its being an essential source for studying the effects of several medicated drugs across the placenta. The association towards the invalidity of the mouse placenta serving as a model for replicating the human placenta is because the physiology of the mouse placenta distinguishes itself quite substantially from the human placenta. The structure of the mouse placenta compares differently to the human placenta due to the mouse placenta consisting of labyrinthine and junctional zones (figure 3). Another reason why the physiology behind the mouse and human placenta differs is because the mouse placenta consists of a three-layered trophoblast (haemotrichorial) while the human placenta consists of a single syncytiotrophoblast zone and layered trophoblast (haemomonochorial) [36, 39, 68] . In addition to the physiological trait variances between the two placentas, scientists are still struggling to replicate the alveolar growth and expansion in the mouse placenta, based on their own prototype alveologenesis. Not to mention, there is still no clear explanation why researchers cannot develop an intact basal membrane that can organize itself into the correct human placental tissue [39] . Contrasting physiology and the inability for scientists to duplicate the biological qualities between the mouse and human placenta are contributing factors towards comparison error and irrelevant data. In this case, the results from tests will have limited valuable data for any success in creating a stable method for the testing of pharmaceutical drugs across the placenta. In order for the in vivo model to become completely practical, the model must recapitulate the functionalities and physiology of a human placenta in almost every way possible, ensuring that the model can be vital towards the testing of pharmaceutical drugs.
Since scientists are struggling to find a solution that diminishes the contrasting physiological barriers between the mouse and human placenta, researchers have been unable to develop a concrete or practical procedure that can carry on any significant medicated drug tests [36] . For example, even though scientists have evaluated tempol, progesterone and thalidomide on the mouse placenta, researchers have been unable to perform a broad range of pharmaceuticals across the mouse placental barrier. For instance, the testing of diabetic or human royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 immunodeficiency virus (HIV) medications-two commonly prescribed medicated drugs to pregnant women-across the mouse placenta should be taking place more often by now, considering that scientists have been working on the in vivo mouse model for decades [69, 70] . Besides all the pessimism that surrounds the mouse model, researchers have successfully devoted the majority of their time trying to modify these mice to mimic human functionalities (table 1), but should consider assessing the effects of pharmaceutical drugs on the mouse placenta more frequently.
Sheep model limitations
While there has been a substantial quantity of testing accomplished on the sheep placenta, the model is an underdeveloped approach towards the testing of medicated drugs on the sheep placental barrier. One reason, particularly, is the fact that the physiological structure and glucose transfer between the sheep and human placenta differ from each other quite substantially. For example, sheep have specialized territories that are well vascularized, while the human placenta has a conceptus that invades into the uterine wall. Sheep also have a considerable amount of individual attachment sites composed of the maternal caruncle and fetal cotyledon; however, the human placenta has a large discoid placenta. In addition to the differences in physiological traits between the two placentas, glucose transporter proteins, GLUT-1 and GLUT-3, are developed and regulated in the sheep placenta but not in the human placenta. Not to mention, GLUT-1 is limited to the base of the syncytial layer of the sheep placenta, but localized in the vascular endothelial cells of the human placenta. This variation in placental structure and glucose transfer gives most scientists less motivation to carry out this method, because of the raised concerns of the invalidity of the sheep placenta serving as a model for replicating the human placenta [42] .
Let alone, although there has been success towards the testing of mineral traces, maternal-fetal structure and interactions, and transdermal fentanyl and triclosan in the sheep placenta approach, scientists have executed a modest number of pharmaceutical tests on the sheep placenta. Researchers have been spending the majority of their time testing the feasibility of the sheep placenta model in order to prove that their models will produce the same natural reactions from pharmaceutical intake that occur in the human placenta. In order for the sheep model to become fully practical, the model first must be able to completely replicate the physiology and functionalities of the human placenta [42] . If not, then the tests will have no significance towards the comparison of data from the performance of pharmaceutical analyses on the sheep placenta to the human placenta. Fortunately, scientists have been testing and ensuring that the sheep model imitates the similar physiological functionalities with the human placenta (table 1), even though the structures between the two placentas differ from each other significantly. Nonetheless, researchers could consider the testing of more pharmaceuticals across the sheep placenta in the upcoming years to ensure that there is a balance between functional analysis and pharmaceutical experimentation on the sheep placenta. Furthermore, the in vivo model of the sheep placenta is in the development stages of replicating the physiology of the human placental barrier, which has been limiting the potential testing of medicated drugs on the model's placenta.
Future of in vivo model development
Although the practicality of the in vivo model for the testing of pharmaceutical drugs on the placenta has been tested in many royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 unique and complicated ways, the use of animals for clinical and experimental trials is facing an extensive loss in support and disappreciation, due to the model's invalidity of transability towards human study [71, 72] . The use of animals for the testing of pharmaceuticals is considered doubtful due to the difference in placentation between humans and other animals. Rodents and mammals also lack the surplus quantity of trophoblasts in the villous structure within the myometrium and endometrium of the placenta. Moreover, financial and ethical constraints, from testing on animals, tend to play a critical role in the lack of resources and motivation for researchers to run trials and experiments on the placenta [73, 74] .
The leading reason why researchers are still analysing this method for studying the human placenta is that drug responses can be predicted and tested most accurately in vivo [71] . Nevertheless, the replacement for the use of the in vivo approach for testing and examining the human placenta will be largely due to the progress and improvement of the placenta-on-achip [35] . The in vivo method is the most primitive method for studying the placenta, and as explained before, the in vivo model has not seen a significant amount of progress in testing pharmaceuticals. In large fault, though, scientists are still in the development stages of the mouse, sheep, and other animal models, in which the models are still being improved upon in order for more pharmaceutical testing to take place [22] . Nonetheless, although the in vivo approach has seen a substantial amount of progress throughout the past couple of decades, the in vivo method lacks current resources and knowledge to carry out an effective universal procedure for in vivo model consisting of mice, sheep and other animals. The testing of animal subjects may seem prominent for other medicated applications; however, because of the complexity of the placenta, the existence of a developed in vivo method for testing the durability and validity of pharmaceutical drugs could potentially lose support in the near future. To ensure the continuation and support for the in vivo approach, scientists could consider the testing of more pharmaceuticals on their animal models in the upcoming future.
Ex vivo
The utilization of the ex vivo approach has been witnessing a decline in scientists' ability to develop a practical perfusion model that can test pharmaceuticals on real human placenta tissue. For clarification, ex vivo means the testing on a live organism is done outside of the host, while in vivo and in vitro studies are conducted in the living host and cultured system, respectively [35] . The ex vivo model serves as possibly one of the most frequently tested, but complicated procedures when engaging in the testing of pharmaceutical drug intake of the placenta. However, most scientists prefer this model over the in vivo method towards the study of recapitulating the features of the human placenta [35] . The reason is that in the fetal and maternal umbilical plasma of a human, calculating the course of a drug is nearly impossible in vivo; however, the ex vivo model has proven to be successful to calculate the course of a drug [75] . Nevertheless, likewise with the in vivo method for replicating the human placental barrier, the ex vivo model of testing is found most frequently in mature placental subjects [76] .
While the ex vivo and in vivo approaches share several similarities and differences, the perfusion model itself has a range of advantages towards the study of the human placenta.
A few of the primary benefits of the human placental perfusion are that the model offers information about placental storage, metabolism, transplacental transfer and vascularization [35] . Another benefit of the ex vivo model is the fact that the approach does not cause severe damage to the maternal vasculature due to being torn from the uterine wall. The cause of interindividual fluctuation in the transplacental transfer is an additional benefit that has also been characterized by the ex vivo perfusion model [77, 78] . The most essential factor when considering the applicability of the ex vivo model is the representation of real human tissue, due to the fact that real human tissue plays a vital role in the performance of perfusion experimental studies [77] [78] [79] . The representation of real human tissue is the justification for why researchers have frequently been using and improving this method, in which their experiments will include the natural reactions that the placenta releases in vivo during pharmaceutical drug intake.
Ex vivo perfusion model
The following models are a human placental perfusion system (figure 4a) and dual placenta perfusion model (figure 4b1 and b2) from Malek et al. [80] and Conings et al. [81] , respectively, who adopted the first ex vivo perfusion model developed by Panigel et al. [82] and later modified by Schneider et al. [83] , Myllynen et al. [84] , Mathiesen et al. [12, 85] , Myren et al. [35] , and other research groups. Circulating (figure 4) and non-recirculating perfusion are the two most prominent types of ex vivo placental perfusion systems. Yet, the circulating model has proved to be a suitable approach when testing perfusion across the placental barrier [77, 78] . For example, the procedure carried out by Myllynen et al. [79] for the experimentation of the ex vivo model to test antipyrine concentration was a major success in reconstructing the placental perfusion model. Since Myllynen et al. have had a substantial amount of success pertaining towards the utilization of their perfusion model, the construction of their perfusion model can be used as an example for the development of an ex vivo placental perfusion [79] . Or, the following studies listed in the next section can be investigated for further information on the construction of an ex vivo placental perfusion.
Studies concerning ex vivo perfusion model
Considering the fact that the ex vivo perfusion model is studied quite frequently among scientists, researchers have been able to conduct a variety of experiments ex vivo. Table 2 presents an array of experiments pertaining to the utilization and application of the ex vivo perfusion model towards the examination and evaluation of pharmaceuticals, toxins and the inner mechanisms of the placental barrier ex vivo. More specifically, table 2 categorizes each work by type of testing, details regarding the study, and conclusions from analysis.
Most of the following tests summarized in table 2 use the circulating placental diffusion model for all experimental analysis, and carry out the perfusion assembly as mentioned in the previous section. However, there are perfusion composition differences between the experiments, which are not necessarily accounted for. Furthermore, previous ex vivo studies have proven to be beneficial when studying the causes and effects that certain pharmaceutical drugs have on the transplacental passage [75] . Many of the pharmaceutical drugs relate to anti-epileptic drugs and HIV protease inhibitors, which have been tested on the ex vivo model since the mid-1990s [36] . As royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 well as the testing and validating of anti-epileptic drugs and HIV protease inhibitors, the ex vivo model has been used to study and test the transplacental passage of exogenous and endogenous compounds and the examination of the transfer of amino acids in the placenta [75, 103] . Additionally, the replication of the effects of diseases like cancer and other drugs has been used as a model for assessing the effectiveness of the placental perfusion [86] . Placental perfusion based on table 2, and the ex vivo model in general, has proven to successfully replicate carboplatin in the human tissue, evaluate the maternal drug transfer across preterm birth, and analyse the functional components of the placental barrier on human placental tissue. In these cases, the ex vivo perfusion model has successfully analysed the reactive behaviour released from the human placental tissue, and provided scientists with accurate understandings on how glucose transfer and placental elasticity affect fetal growth. In addition, researchers have been able to use this knowledge to attain new understandings on how these drugs affect the human placenta, and what can be done to ensure that these drugs do not impose any harm on the mother and fetus. Thus, what can be concluded from the success of the ex vivo model is that the placental perfusion process has not been a misfortune in the model's development.
Future of ex vivo model development
The ex vivo model may present many significant contributions towards the study of the placenta and the effects that pharmaceutical drugs impose on the placental barrier; however, the ex vivo approach does not have a standardized placental perfusion method, due to the difference in perfused compositions [75] . Unfortunately, the ex vivo model does not weigh placental transfer across the entire pregnancy, and cannot necessarily recapitulate the binding to serum proteins in vivo conditions such as rilpivirine, a compound used to study placental transfer [104] . The potential of the ex vivo placental perfusion model has limitations, such as having a laborious placental perfusion set-up procedure and cannot handle the broad scale of chemical testing and screening [79] . Not to mention, the ex vivo model does not last long, because of the model's short lasting performance and output of experimental results [73] . Currently, the model can last approximately 2-4 h and 6-8 h for short and long experiments, respectively [35] . Comparatively, in vitro studies do not include the usage of real human tissue, allowing experiments to last for days on end.
Although one could argue that the practicality of the ex vivo model has proven to be more sustainable than the in vivo royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 toxicity/drug testing testing for antipyrine concentrations ex vivo results revealed that the antipyrine concentrations of both the maternal and fetal concentrations ended up equal, revealing the success of a circulating perfusion model and the model's placental transfer [79] examined the fetal drug compartment concentrations by exposing the placental -trophoblastic barrier with a variety of carboplatin concentrations revealed that fetal kidney cells are affected by the carboplatin and efficiently mimicked carboplatin in real human tissue [86] determined the extent and rate of maternal -fetal transplacental passage of bromocriptine (BCT) ex vivo concluded that only trace amounts of BCT could transport across the human placenta [87] use the ex vivo model for testing the placental transfer of maraviroc proved to be successful and relatable to the in vivo model, due to the accurate ratios in the maternal blood samples and umbilical cord [88] test placental transfer of rosiglitazone in perfusion model discovered that rosiglitazone passes through the placenta at a low rate, and there is minimal fetal accumulation and transfer of rosiglitazone in the placenta [89] measure the transfer of lamivudine across the human placenta ex vivo by simple diffusion, lamivudine appears to pass over the placenta [90] measure the transfer of lamivudine across the human placenta with zidovudine appearance of lamivudine is not altered by the presence of zidovudine in the placenta [90] tested placental transfer of enfuvirtide in perfusion model enfuvirtide placental transfer was not detected or observed, concluding that enfuvirtide can be used in HIVinfected pregnant women without causing harm to the fetus [91] evaluate the maternal -fetal transfer of granisetron in ex vivo perfusion model granisetron has concentration dependent placental transfer, and at systemic granisetron concentrations there is no placental transfer detected [92] test the human placental transfer of hydralazine in ex vivo perfusion model hydralazine crosses the ex vivo perfusion model readily, and the absorption of hydralazine in the fetal compartment was in linear relationship with the maternal concentration [93] examined the transportation of metformin across the placenta using ex vivo model metformin displayed a higher transport rate from the fetal -maternal side, and is mediated by a carrier that is likely part of the organic cation transporter family [94] tested the maternal -fetal transfer of saquinavir in perfusion model low rates of placental transfer of saquinavir were calculated, revealing that the use of this drug will possibly not be exposed significantly to the fetus [95] analysed the placental transfer of pioglitazone and sitagliptin ex vivo significant fetal accumulation of pioglitazone, clearance indexes, and extended half-life of pioglitazone and sitagliptin are not tolerable for treating diabetes during pregnancy [96] evaluated the transplacental transfer of oseltamivir using ex vivo perfusion model the transplacental transfer of oseltamivir phosphate was detected significantly, revealing that the results might have clinical importance
that can test the effects that medicated drugs and other diseases can impose upon the placental barrier. To argue rather, the perfusion model has seen significantly more progress in medicated drug testing than the in vivo approach and has had more success with the model's experiments dealing with the replication of antipyrine, placental transfer of maraviroc, and maternal drug transfer across preterm birth. Support for this claim can be found and exemplified in the variances in quantities of medicated drug testing between tables 1 and 2. Nevertheless, the model has limitations and is arguably a difficult procedure to carry out effectively due to the short-lasting performance of the model, time composition, inability to handle a considerable amount of chemicals, and other constraints. In order for the ex vivo model to not see a decline in the support in the placental perfusions continuation to run tests for pharmaceutical effects across the placenta tissue, scientists should consider developing a fully practical and universal model that diminishes the differences between perfused compositions and other limitations. In large fault though, the ex vivo approach will likely see a decline in the support of the model's experiments, due to the increasing interest and improvements in the in vitro approach.
Placenta-on-a-chip

Microfluidic devices
The placenta-on-a-chip model ( figure 5 ) is the closest to the completion of a practical model that can replicate the physiology and functionality of the human placenta for the testing and transability of pharmaceutical intake from an in vitro model to an in vivo human placenta. Microfluidic devices serve as the foundation and system for the testing and analysis of pharmaceuticals in the in vitro model. The development of the distinct physical setting of the microfluidic devices enables researchers to culture and manage the cellular and subcellular environments, and maintain a definite arrangement of the cells [106, 107] . Microfluidic systems additionally allow researchers to gather the most significant amount of data in the shortest period of time, reduce sample utilization, and mimic the flow of fluids in parallel layers [108] [109] [110] [111] [112] [113] . A large portion of the microfluidic device's abilities were developed and managed by a handful of research groups, Sadao et al. [119] , who have spent the past decade developing and modifying microfluidic devices for drug, cellular, and tissue analytical simulation studies. Moreover, many of these advantages are influenced by the chip's capability to structurally withstand the co-culturing of endothelial and trophoblast cells. An important component of the microfluidic device, and the in vitro model in general, is that the placentaon-a-chip requires the representation of endothelium and trophoblastic epithelium in order for the replication of the fetal and maternal interfaces of the placenta. When the endothelium and trophoblastic epithelium in the human placenta are represented accurately, the in vitro model can perform a variety of tests that replicate the physiology of the placental barrier, and the circulation of pharmaceutical intake and diseases between the mother and fetus. The functional analysis characterize placental oxygenation levels ex vivo heterogeneity was displayed through intervillous space oxygen mapping, and discovered that whole placental lobules displayed 3D placental oxygenation maps at great resolution [98] analysed the feto -placental vasculature of the placenta using perfusion model ex vivo model can efficiently evaluate the dependency of Doppler ultrasound clinical measures for placental obstruction [99] examined the transportation of immunoglobulin G (IgG) ex vivo the human placenta develops a specific transport mechanism for IgG for the fetal and maternal direction [100] examined the transportation IgG subclasses ex vivo transfer rates for all four classes varied. IgG 1 had the preferential transfer, while IgG 2 had the slowest transfer [100] evaluated the differences of placental elasticity between normal and IUGR pregnancies using perfusion model IUGR group displayed more histopathological changes and were stiffer than the control group, and that reduced placental elasticity could be the cause of these differences [101] examined the maternal transfer of interleukin-6 in the ex vivo perfusion model minimal maternal to fetal transfer of interleukin-6 was observed from the ex vivo perfusion model [102] royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 growth factors, cytokines, hormones, nutrients, intercellular junctions and extracellular matrices are all additional examples of soluble and insoluble aspects that can be mimicked through the use of a microengineered co-culture model of a placenta-on-a-chip [72] . Data and tests have also proven well for microfluidic devices, and have opened the doors to a realm of organson-chips [120] : bone-on-a-chip [121] , liver-on-a-chip [122] , body-on-a-chip [123] , kidney-on-a-chip [124] , lung-on-a-chip [125] , cancer-on-a-chip [126] , heart-on-a-chip [127] and brain-on-a-chip [128] . The following organs-on-chips reveal that the on-a-chip process is used quite frequently in the medical industry, and is becoming ever so demanding for the better understanding of the human body. For example, the in vitro models have proven to successfully develop treatments for diabetes, leukaemia and hyper-cholesterol [74] . Nonetheless, most scientists can agree that the microengineering of the placenta-on-a-chip serves as the most practical model that requires the smallest budget compared to the ex vivo and in vivo approaches, and procedure to test pharmaceutical intake on the in vitro model's cultured cells and membranes. Overall, though, the 3D cell-culture model proves to be compatible and capable of withstanding the ability to support tissue differentiation, cell growth and growth factors. In this case, there has been a growing interest in the placenta-on-a-chip's ability for scientists to directly manipulate human endothelial and trophoblast cells.
The microfluidic device (figure 6) serves as the primary support for the placenta-on-a-chip and must be fabricated efficiently before cell culture, cell seeding in the chip, and analysis of the placental barrier can be performed [5] . Several research groups, including Miura et al. [105] , Lee et al. [130] , Blundell et al. [5, 131] , Zhu et al. [129] , Yin et al. [132] and Pemathilaka et al. [133] , have carried out the previously stated procedures for their placenta-on-a-chip. In this case, the groups were able to successfully prepare and combine microfluidics and biology, produce confluent layers of endothelial and trophoblast cells within the chip's channels, and perform experimental analyses on their placenta-on-a-chip. Therefore, their experimental methods will be elaborated in the next few sections. Detailed information about each group's fabrication methods, cell culture, microfluidic cell seeding, and verification of the placental barrier can be found in the electronic supplementary material.
Through the studies listed in [132] and Pemathilaka et al. [133] have successfully created a placenta-on-a-chip. The fabrication process for their microfluidic devices is a concrete and universal procedure method that most scientists use. The reason why is because the model allows researchers to compare their tests and results due to the consistency of their fabrication process. Since fabrication was performed adequately for all the studies, and similar culturing and seeding methods were used among the variety of royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 Table 3 . Summary and comparison of placenta-on-a-chip experiments. royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 [129] nanoparticles TiO 2 nanoparticles accumulated and transferred across the maternal channel the integrity of cell junction, production of reactive oxygen species (ROS), and adhesion of maternal macrophages were explored microvilli formation in trophoblastic cells was examined GLUT1 was expressed in the maternal channel no dramatic alternations in ROS production were detected microchip can be used as a platform to investigate nanoparticles in human placenta in vitro model possesses the capability to examine food safety and environmental toxins in a human placental barrier in vitro
BeWo cells (maternal channel) HUVECs (fetal channel) [132] caffeine cell detachment was reported to cause fluctuations in caffeine concentrations semipermeable membrane integrity proved efficient over time caffeine rates warranted further investigation caffeine absorption was identified across the edges of the maternal channel's PDMS walls placenta-on-a-chip can be used as a platform for investigating caffeine concentrations in human placenta in vitro microfluidic device provides a platform for xenobiotic testing BeWo cells (maternal channel) HUVECs (fetal channel) [133] royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 experiments, analysis of their placental barriers produced satisfactory results pertaining to the confluence of trophoblast and endothelial cells. In this case, their microfluidic devices were prepared for the study of glucose, glyburide, heparin, bacterial infection, nanoparticles and caffeine across their microengineered barriers. Moreover, the placenta-on-a-chip microengineered approach has a well-developed procedure that is being progressed to replicate the physiology and pharmaceutical intake of an in vivo placenta.
6. Experiments and analysis from placentaon-a-chip 6.1. Glucose
The replication of the physiology and transfer of fluids of the human placenta in the in vitro model is the most crucial step towards the testing of pharmaceuticals across the placenta-ona-chip because the in vitro model must completely reproduce the natural reactions that the human placenta releases when confronting pharmaceutical intake. The analysis and study of the glucose transfer across the placenta-on-a-chip barrier is a significant and logical way of studying the strength, reactiveness, and fluid flow of the model's co-cultured placental barrier. Glucose serves as a vital factor during normal pregnancy when transporting overt and gestational diabetic medication on the placental barrier. Glucose is also predominantly found across the placental barrier [105, 130, 134] . Two examples of the testing of glucose across the in vitro model's placental barrier can be found in Lee et al. [130] and Blundell et al. [5] experiments, which adopted a similar approach for the glucose perfusion. Lee et al. began the testing and analyses of glucose transfer across their placenta-on-a-chip by introducing glucose concentrations to the fetal and maternal sides of the chip. EGM TM -2 containing a lower glucose concentration (1.1 g ml
21
) was introduced to the endothelial channel, while Dulbecco's modified Eagle's medium (DMEM) supplemented with a higher concentration (4.5 g ml
) of glucose was added in the trophoblast channel. The introduction of these glucose concentrations replicates glucose gradients across the placental barrier, so the in vitro membranes release a more recognizable reaction that mimics the behaviour of an in vivo placenta. Next, 30 ml h 21 of a continuous flow of the glucose-supplemented culture media was maintained in the channels for 68 h. Lastly, the outlets at the end of the lower and upper channels were used to collect the perfused media. An evaluation of the lower maternal compartment's reduction in glucose concentration was also conducted to determine if gradient-induced passive diffusion or glucose transporters were responsible for fluctuations in glucose concentrations across the chip. Analysis from the placental cells revealed that glucose transporters were a significant factor towards the differences in maternal and fetal glucose concentrations, as well as gradient-induced passive diffusion [130] . Blundell et al. began the placenta-on-a-chip glucose study by perfusing the maternal channel with F-12 K medium, supplemented with 10 mM of glucose to increase the glucose concentration levels generated by F-12 K medium. Nonetheless, on the fetal side, the media contained 5.5 mM of glucose during perfusion. During the perfusion process, outflow from both microchannels was collected over a 2 h period. The collected flow was analysed by a glucose meter, that measured glucose concentrations [5] .
The results carried out in the testing and analysis of glucose transfer rates turned out to be successful and revealed metabolic consumption. Lee et al. results indicated that the final transfer rates of the co-culture model yielded from 17.3 to 39.1%, which is approximately in the same range of the in vivo transfer rates [130] . Similar rates can also be compared to Blundell et al. placenta-on-a-chip glucose transfer rates. Blundell et al. microchip produced a glucose rate of 34.8%. The following glucose transfer rate was found to be in the same region as that of an ex vivo glucose study, that produced glucose rates from 26.5 to 38.3% (figure 7c) [5] . Based on observation, the yielded glucose rates from both Lee et al. and Blundell et al. shared similar rates to those of an in vivo placenta and an ex vivo study, respectively, indicating the proficiency of both glucose experiments. Successful and related results of the following analyses reveal the in vitro model's ability to mimic the structure and placental transfer of glucose in an in vivo human placenta. More importantly, the model's ability to replicate glucose transfer rates provides evidence that the model is prepared for the perfusion of medicated drugs [5, 130] .
Glyburide
The progress of the in vitro model for the replication of the physiology and glucose transfer across the in vivo placental barrier has played a significant part in the replication and comparison of medicated drug reactions between the placenta-on-a-chip and in vivo human placenta. For example, the testing of glyburide across the placenta-on-a-chip proved to be successful in replicating the common occurring effects that the in vivo placenta releases during glyburide intake. Glyburide is a common medication that is prescribed to pregnant women to combat and contain diabetes. However, the traceability of glyburide is nearly undetectable in the fetal circulation as reported by the success of the ex vivo clinical and perfusion models [131, 135, 136] .
Nonetheless, with the development of the placenta-on-achip, Blundell et al. have efficiently imitated the usual effects that the human placenta releases when glyburide is diffused across the placental barrier (figure 8). The study began when Blundell et al. introduced glyburide into their placentaon-a-chip. The continuous perfusion of BODIPY-conjugated glyburide diluted in serum-free DMEM/F-12 K to a final concentration of 1 Â 10 26 M was perfused through the maternal channel, while the EGM-2 medium was injected into the fetal channel to examine glyburide transport. After a 30 min equilibrium phase, the outflow was collected from the fetal compartment in 30 min intervals and then analysed with a microplate reader. Next, to validate the presence of breast cancer resistance proteins (BCRP), Ko143 (150 Â 10 29 M in dimethylsulfoxide), an inhibitor of BCRP, was included in the drug-containing medium and perfused in the maternal channel [131] . After testing was completed, Blundell et al. began interpreting their data. Low concentrations were measured throughout the first 3 h due to the large absorptions from the polydimethylsiloxane (PDMS) slabs, and trophoblast cells. Unexpectedly the concentrations began to rise in the last 3 h of the experiment, resulting in glyburide rates of 5.6% which were relatively close to the ex vivo model's glyburide rates from 0.62 to 3.9%. These sudden rises were most likely caused by BCRP-medicated active transport of BODIPY-glyburide, in which the royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 placental barrier was absorbing BODIPY-glyburide back into the maternal circulation. Nevertheless, the similar results between the in vitro and ex vivo model reveal that the simple in vitro chip's design can duplicate the active drug transport of an in vivo human placenta, like the complicated and underdeveloped ex vivo model was able to accomplish [131] .
Observations were also taken from the constant fetal concentrations of glyburide. The fetal concentrations turned out to be lower than the maternal concentrations. In addition, microscopic imaging was carried out to determine why there were differences in the fetal and maternal concentrations. Based on microscopic imaging, observations conclude that BeWo cells were predominantly in control of glyburide transport. This observation indicates the fact that BeWo cells in the in vitro model were one of the most significant aspects towards the transporting of glyburide across the chip's barrier, which happens in most cases in an in vivo placenta [131] .
Blundell et al. microengineered placental barrier was also analysed to determine the presence of BCRP, major efflux transporter in the placental tissue. The BCRP plays a critical royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 role in preventing medicated drugs from entering the fetal compartment of the placenta, making the presence of BCRP essential for the in vitro model to mimic the diffusion of drugs across the placental barrier completely. Based on fluorescent images, BCRP turned out to be distributed throughout the trophoblast channel of the in vitro model, which is parallel to the in vivo human placenta. Nevertheless, including Ko143 in the perfusion of BODIPY-conjugated glyburide reduced the transport function BCRP and prevented the BeWo cells from transferring glyburide back into the maternal channel. This discovery supports the presence of BeWo cells when glyburide is moved across the placental barrier, supporting the previous argument. Therefore, the placenta-on-a-chip's progress, pertaining to the model's ability to reproduce the natural reactions that are released from an in vivo placenta when confronted with glyburide, reveals one of the chip's highlighted accomplishments [131] .
Heparin
Not only was there success pertaining to the replication of glyburide in the in vitro model, but the replication of the natural effects of heparin in the placenta-on-a-chip was carried out successfully as well. Heparin is a commonly used medication to prevent vein thrombosis and arterial thromboembolism. Not to mention, heparin is a commonly used anticoagulant medication to assess the microengineered placental interface's barrier integrity. Blundell et al. assessed heparin transport across the placental membrane and measured the intensity of fluorescence outflow from the microchambers of the placenta-on-a-chip. The analysis of heparin transport was also carried out in order to determine if the in vitro model can efficiently duplicate the maternalfetal interface and restrictive barrier of an in vivo placenta. Using heparin as a medicated drug subject additionally allowed researchers to verify that their in vitro model fully imitates the common reactions from an in vivo placenta in order to acknowledge the model is entirely practical [131] . At the beginning of the study, Blundell et al. diluted green fluorescent fluorescein-heparin conjugate to a concentration of 0.05 mg ml 21 in DMEM/F12 K medium. Subsequently, the diluted fluorescein-heparin was injected into the maternal compartment of the placenta-on-a-chip. Following 5 h of perfusion, the outflow was then collected from both channels. The fluorescence levels were then quantified with a microplate reader. The following procedure was carried out for both the coculture and bare membrane (acellular) conditions in the microchip. Briefly, the acellular system included a bare semipermeable membrane without the support of trophoblast and endothelial cells; however, the coculture system was supported with BeWo cells and human placental vascular endothelial cells (HPVECs), and consisted of lower fluorescence intensity [131] .
Results from the acellular devices indicated high fluorescence levels and a concentration of 11.3% of the maternal compartments' initial absorption. High fluorescence levels and low concentrations prove that the acellular device efficiency replicated the natural reactions released from an in vivo placenta from heparin intake. The co-culture system resulted in a fluorescent final fetal concentration of 0.2% of the maternal concentration initial value. This lower concentration that of the acellular device can be explained by the presence of BeWo cells and HPVECs. Nonetheless, the 11.3% and 0.2% minuscule concentration percentages reveal that Blundell et al. placental barriers can effectively mimic the case that heparin was reported to be not transported across the placenta barrier due to its larger molecular size. In this case, the placenta-on-a-chip can successfully replicate the natural occurring reactions from heparin intake, in which the in vivo placenta's common response from heparin is to show aggressive rejective behaviour. Testing heparin in the in vitro model provided support for the fact that the placenta-on-a-chip possesses the ability to test for medicated drug intake reactions. More importantly, though, the study's success establishes that the microchip's similar fabrication processes with the glucose and glyburide studies prove that the placenta-on-a-chip is closing in on becoming the practical model for revolutionizing pharmaceutical drug testing [131] .
Bacterial infection
Zhu et al. chose to model placental inflammatory responses to bacterial infections through their microfluidic device ( figure 9 ). Through the establishment of the microfluidic device, they were able to construct a placenta-on-a-chip that enabled them to analyse tissue and cellular responses to bacterial infections. Bacterial infections are a common cause of placental inflammation that can cause damage to fetal organs and transplacental infection in the growing fetus. In return, these damages can cause inflammatory response syndrome, sepsis and other underlying diseases within the human placenta. In these cases, these responses can lead to short-term and longterm limitations during fetal development stages. Therefore, scientists need to be incorporating bacteria into the placentaon-a-chip if they want to account for these limitations and fully replicate the physiology of the human placenta in vitro [129] . Bacterial transformation and infection within Zhu et al. chip began with the cultivation of Gram-negative Escherichia coli (E. coli) labelled with a green fluorescence protein (GFP) from LB broth. Escherichia coli is a dominant bacterium found within the intestines of humans and other animals, which happens to be harmful in most cases. Cultivation took place for 12 h at 378C and 5% CO 2 . Subsequently, the E. coli were resuspended in DMEM/F-12 K medium and immunized with trophoblast medium in the upper microchannel of the microfluidic device. After 6 h of immunization, the cells were prepared for biological analysis [129] .
Results and data from biological investigation concluded that the immunization with the E. coli and trophoblast cells resulted in high amounts of inflammatory cytokines, which include interleukin-1a (IL-1a), IL-1b, and IL-8. In other words, there were increased levels of inflammatory cytokines from the immune responses (IL-1a), cell proliferation (IL-1b), and the host defence mechanisms (IL-8). These increased levels of inflammatory responses resulted in a significant amount of death in the trophoblast and endothelial cells. The conclusion from these results reveals that the placenta-on-achip was able to mimic the inflammatory reactions on an in vivo placenta when confronted with E. coli, based on the similarly increased levels of inflammatory responses. Nevertheless, conclusions from the Zhu et al. study also indicated that the BeWo cells activated the circulating macrophages when inflammatory responses began to develop along the maternal side of the chip. These activation interactions are common in an in vivo human placenta, since the macrophage responsibilities include the protection of the maternal and fetal organs from bacterial inflammatory infections. Thus, these results royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031
show the placenta-on-a-chip's capabilities to replicate the bacterial interactions and behaviours between the macrophages and trophoblast and BeWo cells in vitro [129] .
Nanoparticles
The placenta-on-a-chip has been applied for fluid analysis, medicated drug testing, physiological examinations; however, Yin et al. used their in vitro model for nanoparticle (NP) analysis (figure 10). The study included common NPs (TiO 2 -NPs) that are environmentally exposed to the majority of pregnant women. Unfortunately, studies lack on this subject of research, so the adverse effects NPs on the placental barrier are less known. However, through the fabrication of Yin et al.
placenta-on-a-chip, they were able to extrapolate data to explore the effects TiO 2 -NPs on their microengineered placenta while bringing awareness to this overlooked NP [132] .
Yin et al. began this experiment by exposing their fabricated placenta-on-a-chip with NPs. The process began by injecting DMEM/F12 K medium with TiO 2 -NPs at a concentration of 50 was acquired from a confocal microscopy, Yin et al. began ROS detection in their cells. The inspection was conducted using a ROS assay kit [132] .
The findings Yin et al. gathered begin with their ROS fluorescence image discoveries. The production of ROS, a natural occurring metabolism by-product in trophoblast, was used to study when detecting for NP exposure. On the maternal side of the chip, when lower NP concentrations were introduced, ROS generation was almost nondetectable. Once levels were increased, ROS generation activated substantially, which is observable based on the decrease of cells. Additionally, once the NPs transferred across into the fetal channel of the microchip, endothelial cells began to die off. These increased distributions were in theory enhanced by the close-fitting cellular junctions within the placental barrier. Therefore, tight junctions are possibly more sensitive to environmental stress and NPs. Nevertheless, since the placental barrier includes more than just endothelial and trophoblast cells, Yin et al. decided to analyse the effects the NPs had on macrophages [132] .
During the procedural examinations, monocyte adhesion was included. Based on the discussion of Zhu et al. study on bacterial infections, monocytes are prominent for cellular and tissue defence from outside pathogens [132] . Once data were collected from the NP channel exposure, macrophages were introduced into the maternal side of the chip. Observations discovered that the macrophages adhered to the trophoblastic cell layer. This behavioural reaction revealed the significant immune system changes towards NPs. In other words, macrophages were able to detect the NPs and determine the harmfulness of their nature. Moreover, the results of the study concluded the destructive nature of NPs, and the damaging effects they impose on the placental barrier. In this case, these destructive behaviours can have a long-term impact on the placenta, and even worse, the fetus [132] .
Therefore, in conclusion of the study, there are two take aways. One, the fabrication of the placenta-on-a-chip was carried out similarly to the previous elaborated studies, providing consistency between analyses. More importantly, though, the placenta-on-a-chip was used to study an overlooked pathogen-a pathogen that scientists have not been paying close attention to when searching for mutational defects in the fetus and placental barrier. So, in this case, the study provides one of the first documentations on the effects NPs impose on the placental barrier, based on their placenta-on-a-chip. In this case, this study will improve placenta-on-a-chip progress for medicated drug testing, considering NPs play a role in placental mutations and fetal birth defects [132] .
Caffeine
While placenta-on-a-chip has undergone fluid flow, medicated drug, bacterial infection and NP testing, Pemathilaka et al. provide one of the first studies of caffeine transport across the placenta using a placenta-on-a-chip model ( figure 11 ). Caffeine happens to be one of the most widely consumed stimulants in the world and is a main ingredient in coffee, tea, chocolate, soda, etc. In this case, the over-consumption of caffeine can have damaging effects on the fetus. So, in this study, Pemathilaka et al. fabricated a placenta-on-a-chip to assess the overlooked behaviours the xenobiotic compound is imposing on their chip. Or, particularly, to compute the rate of caffeine transport across their microengineered placental barrier [133] .
Initially, a 0.25 mg ml 21 caffeine solution was suspended in F-12 K medium and then introduced into the maternal channel. After 1 h of perfusion period, the samples were collected from both the maternal and fetal channels of the chip (electronic supplementary material, figure S1), thereafter for every 30 min. The sample preparation process started by diluting collected caffeine samples with methanol (1 : 3) and vortexed for a few seconds and then centrifuged at 16Âg for 5 min. Each sample was analysed through a liquid chromatography mass spectrometry analytical method to determine the caffeine concentrations, which included measuring the intensity of protonated molecular ions of caffeine at m/z 195 and establishing a caffeine calibration curve to quantify caffeine in the maternal and fetal channels. The mobile phase was prepared through the resulting mixture: water (80% with 0.1% acetic acid) and acetonitrile (20% with 0.1% acetic acid), and flow rate and injection volume were maintained at 0.75 ml min 21 and 5 ml, respectively. Once testing was finished, Pemathilaka et al. concluded that their model had successfully shown variations in transfer rates based on caffeine injection [133] . Based on the results, Pemathilaka et al. placenta-on-achip produced steady-state caffeine concentrations of 0.0033 mg ml 21 after 5 h and 0.1513 mg ml 21 after 6.5 h in the fetal and maternal channels, respectively. Discoveries within the study could lead to future investigations of personalized studies that inform the mother whether or not her caffeine intake is imposing any harm to her fetus. Therefore, this model provides the public and scientific community royalsocietypublishing.org/journal/rsfs Interface Focus 9: 20190031 with a platform for future xenobiotic compound testing. In this case, this form of testing is improving the progress and development of pharmaceutical drug testing in the placenta-on-a-chip [133] . While the placenta-on-a-chip is one of the most recently developed approaches towards medical drug treatment, the model has seen a significant amount of progress regarding fluid, medicated drug, bacterial infection, NP and xenobiotic testing. With limited testing and analysis, the success to fail ratio for the placenta-on-a-chip is substantially high, considering that the model was developed relatively recently. A substantial amount of progress has been gained from the broad spectrum of testing in the in vitro model's placental barrier: mimicking glucose transfer, glyburide and heparin drug reactions, bacterial infections, and NP and caffeine exposure responses. The variety of studies, especially the testing of fluid transporters and bacteria and xenobiotic compounds, improves the overall functionality of the in vitro approach, reproducing the physiological characteristics and common reactions that an in vivo placenta releases when confronted with medicated drugs. Most importantly, the consistency between the experiments and their fabrication processes for their microengineered in vitro models has played a vital role towards chip practicality, when comparing data between different fluid, pharmaceutical, bacterial, and xenobiotic intake tests. Therefore, the testing of glucose, glyburide, heparin, bacterial infections, NPs and caffeine has proven to be significant for the better understanding of their interactions with the human placental barrier. As researchers continue improving the fabrication process, and conducting successful medical treatment tests on the in vitro chip, the placenta-on-a-chip could potentially become one of the most in-demand products in the pharmaceutical and medical industry.
Challenges of placenta-on-a-chip
Although the placenta-on-a-chip (figure 12) has made a substantial amount of progress towards the testing of medicated drugs across the microengineered placental barrier, the model was developed fairly recently compared to the in vivo and ex vivo models. One of the most significant problems when defending the placenta-on-a-chip's accomplishments is the fact that the model has only had a few efficient pharmaceutical intake tests performed on the chip's microengineered placental barrier. This is largely because scientists have been devoting the majority of their time in the past few years to modifying the fabrication process for the placenta-on-a-chip. Ironically, though, while scientists have been investing a considerable amount of time improving the chip's structural and functional components, researchers lack the replication of prominent physiological characteristics of the placental barrier. For example, the placenta-on-a-chip lacks the testing of fatty and amino acids, which are essential characteristics when predicting the capability and reactiveness of the chip, and mimicking the physiology of the human placenta [5] . However, unlike the in vivo and ex vivo models, the in vitro approach has seen a significant amount of testing in the model's early development stages compared to the previous models.
Not only are there issues pertaining to the model's experience with pharmaceutical testing, but also faces challenges towards the chip's aptitude to perform complicated tests, and control and distribute PDMS. For example, when the functionality and complexity of the 3D co-cultured model of the cell increases, analysis of the chip becomes more difficult to perform high-resolution screening of the tissue and to visually locate the tissue [137] . In addition, when analysing for biological responses the chip's small cell volumes, when compared to an in vivo placenta, give rise to detection sensitivity issues for drug absorption and cellular interactions. Therefore, the mapping and interpretation of the chip's clinical endpoints make the data difficult for pharmacists and scientists to translate to patients themselves [72] . There are also limitations dealing with PDMS. PDMS has been shown to reduce the pharmacological and drug absorption reactions, because of the PDMS consuming hydrophobic molecules. PDMS also lacks the ability for vast-scale manufacturing, because the PDMS fabrication process is intended for laboratory prototype only. In this situation, the adoption of this technology into the pharmaceutical and medical industry will make the process difficult for large-scale industries to obtain PDMS [72, 131, [138] [139] [140] . Furthermore, the complexity and limitations with the placenta-on-a-chip and PDMS are both major disadvantages when considering the operation and control of the chip's abilities and performance.
More challenging, though, the placenta-on-a-chip lacks the maintenance for human cells and accountability of placental alterations during pregnancy. Scientists can agree that the maintenance of confluent trophoblast cells is challenging. In order to maintain and control confluent trophoblast cells, patience and precise cellular cultivation are needed for the operation and control of the model to function properly. Maintaining and preventing cellular contamination is also difficult when considering that the contamination of the cells will lead towards false results and insignificant data. Additionally, there need to be new developments within the chip in order to account for alterations in an in vivo placental barrier throughout pregnancy. The human placental barrier goes through many alterations in the course of pregnancy. Thus, the model must account for these alterations in order for the chip to entirely mimic pharmaceutical intake of an in vivo placenta during the course of an entire pregnancy [131] . In this case, if the model is unable to account for placental developments during pregnancy, the chip will oppose the model's own goal of being fully practical. Nonetheless, if scientists continue improving upon the chip's performance and sustainability of more challenging analysis, then the model's advantages will overshadow the placenta-on-a-chip's low track record of tests, complexity of transability and evaluation, maintenance of PDMS and cells, and other disadvantages.
The continuation of support and funding for the placentaon-a-chip will assist scientists to progress improvements and developments on the chip's overall functionality. As researchers continue innovating upon the in vitro approach, scientists will be able to conduct an array of tests across the microengineered barrier, other than pharmaceutical testing. For example, the experimentation and analysis of diseases and bacteria could be tested more frequently when the model reaches a sturdier compatible barrier. Scientists will also be able to possibly use the in vitro model to gain new knowledge on the development stage of the fetus. For instance, there will be gains in the understandings of how slower or faster, or altered or damaged developments in the placenta impact the fetus's growth. Nevertheless, the practicality of a universal model was discussed in detail, which dealt with the fact that the model must have a concrete procedure and method that can fully imitate the physiological characteristics of an in vivo human placenta, and be carried out in the same manner for all medical related testing in order for the comparison of data to take place. The development of a practical model that can run medicated intake tests is important towards the better understanding of the effects that pharmaceuticals impose on the fetus and placental barrier. In this case, the placenta-on-achip, as explained throughout most of the paper, was discussed in detail on how this practical model will revolutionize pharmaceutical testing for a better understanding of how medicated drugs affect the human placenta when compared to the in vivo and ex vivo approaches. In conclusion, the application and progression of the placenta-on-a-chip's testing of medicated drugs and improved understanding of the human placenta will help scientists decrease birth defects from medicated drugs, and develop a better understanding of how these drugs affect the human placenta.
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